Skip to content
Evigrade
ModerateSelective reversible acetylcholinesterase inhibitor×Class Ic antiarrhythmic

Updated · Methodology

Mechanism

Post-marketing reports with donepezil describe QTc prolongation and torsade de pointes, so the SmPC asks for caution when donepezil is combined with drugs known to prolong the QTc interval (donepezil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide itself prolongs the QT interval and widens the QRS complex by 12–20% (flecainide SmPC, AEMPS). According to the US flecainide label, flecainide prolongs the QT interval by about 8% on average, mostly through QRS widening. Rare cases of torsade de pointes have been reported with flecainide (flecainide label, US Food and Drug Administration, FDA). The second mechanism involves cardiac conduction. Like other cholinesterase inhibitors, donepezil can have vagotonic effects and cause bradycardia and sinoatrial or atrioventricular block (donepezil SmPC, AEMPS, and Aricept label, FDA). Flecainide slows conduction in all parts of the heart and can cause sinus pauses and atrioventricular block (flecainide label, FDA). The documents say nothing about either drug changing the levels of the other.

Symptoms

The documents describe the risks of each drug rather than symptoms of the pair. Bradycardia, syncope and seizures have been reported in people taking donepezil, and heart block or long sinus pauses may cause them (donepezil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide can cause sinus bradycardia, sinus pause or arrest, second- and third-degree atrioventricular block, and new or worsened arrhythmias (flecainide label, US Food and Drug Administration, FDA). QT prolongation carries a risk of torsade de pointes. Post-marketing reports describe such cases with donepezil (donepezil SmPC, AEMPS), and rare cases have occurred with flecainide (flecainide label, FDA).

Management

The documents do not prohibit this combination. The donepezil SmPC asks for caution with drugs known to prolong the QTc interval and says electrocardiogram (ECG) monitoring may be needed (donepezil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide itself prolongs the QT interval and widens the QRS complex (flecainide SmPC, AEMPS). Before starting flecainide, correct hypokalaemia, hyperkalaemia and other electrolyte disturbances, as well as severe bradycardia and marked hypotension (flecainide SmPC, AEMPS). Use donepezil with caution in hypokalaemia and hypomagnesaemia (donepezil SmPC, AEMPS). Do not give flecainide to people with sinus node dysfunction, atrioventricular conduction defects, second-degree or higher block, or bundle branch block unless pacing is available (flecainide SmPC, AEMPS). The slower heart rate caused by donepezil matters most in sick sinus syndrome and sinoatrial or atrioventricular block (donepezil SmPC, AEMPS). If syncope or seizures occur, consider heart block and long sinus pauses (donepezil SmPC, AEMPS). If second- or third-degree atrioventricular block or right bundle branch block with left hemiblock occurs, stop flecainide unless a temporary or implanted pacemaker is in place. Aim for the lowest effective flecainide dose to limit its effect on conduction (flecainide label, US Food and Drug Administration, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Donepezil

Other interactions with Flecainide